Loading...

MGC Pharmaceuticals Limited

MGCLF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.27
$0.007(2.88%)

MGC Pharmaceuticals Limited (MGCLF) Stock Overview

Explore MGC Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for MGCLFStats details for MGCLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MGCLFAnalyst Recommendations details for MGCLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.

CEO

Mr. Roby Reuven Zomer

Headquarters

1202 Hay Street, West Perth, WA

Founded

2017

Frequently Asked Questions

;